0.52Open0.52Pre Close0 Volume297 Open Interest22.50Strike Price0.00Turnover381.24%IV299.65%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.52Extrinsic Value100Contract SizeAmericanOptions Type0.1360Delta0.0429Gamma23.04Leverage Ratio-0.0280Theta0.0003Rho3.13Eff Leverage0.0029Vega
Annovis Bio Stock Discussion
NEWS
Annovis Announces New Publication in a Peer-Reviewed Journal
Annovis has published a new article in Biomolecules focusing on Posiphen's pharmacokinetics across different species. The study provides a comprehensive comparison of Posiphen's absorption and metabolism in mice, rats, dogs, and humans. Key findings include fast peak concentration in the plasma, high brain and CSF absorption, rapid clearance from the system, and prolonged retention in the brain. Posiphen's p...
Annovis Bio - Believe FDA Will Accept Buntanetap for Symptomatic Relief,Will Allow to Continue Next Pivotal Phase III Study for Disease-Modification
📊⚡️📊
No comment yet